trending Market Intelligence /marketintelligence/en/news-insights/trending/lHZiUqhfM5uLjnR0Bjm6fg2 content esgSubNav
In This List

US appeals court upholds Supernus antiepileptic drug patent

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


US appeals court upholds Supernus antiepileptic drug patent

Supernus Pharmaceuticals Inc. won an appeal case related to Oxtellar XR, its antiepileptic drug.

The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey District Court decision that said Actavis infringed on two Oxtellar XR patents. The appeals court also upheld all three Oxtellar XR patents.

Actavis changed its name to Allergan PLC in 2015, though some parts of the business continued to operate under the Actavis name.